Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Italy / NCT06875414
Recruiting Observational

Breast Cancer and Resilience in Couple

NCT06875414 · tracked via the Priya Life Science Italy tracker
Sponsor
Regina Elena Cancer Institute
Phase
Observational
Started
2022-11-14
Last updated
2025-03-13

Condition(s) studied

Breast NeoplasmsQuality of Life

Investigational drug(s) / intervention(s)

Nursing care model

Nursing care model: Describe relation between resilience, quality of life and depression and marital adaptation in the population considered from diagnosis to 24 months later.

Study summary

This is a prospective pilot study examining the couple's dyadic attitudes from diagnosis to 24 months later when one member is affected by illness and the adaptive strategies the couple employs when stressful events occur.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
INCLUSION CRITERIA: * Woman diagnosed with stage 1, 2 or 3 breast cancer * age\> 18 years (patient and partner) * The partner must have lived with the woman for at least 6 months at diagnosis and treatment * Patients under treatment at the radiotherapy clinic * Subjects available and able to answer questionnaires, interviews, and / or participate in focus groups * Informed consent EXCLUSION CRITERIA: Cognitive deficits and / or inability to comply with the provisions of the study

Primary outcome measure(s)

  • EORTC-QLQ C30 — 24 months
    The questionnaire EORTC-QLQ C30 (Kaasa, S., Bjordal, K., Aaronson, N.,1995) will evaluate the quality of life and will be administered to patients and their partners during a scheduled check-up visit at the Institute

Trial sites (1)

FacilityCityRegionStatus
IRCCS Regina Elena National Cancer Institute Roma Rome Recruiting

More Regina Elena Cancer Institute trials in Italy

Sbrt±sTad for Unfavorable iNtermediate rIsk/High Risk Prostate caNcer Recruiting
Immune Metabolism Dysregulation and Efficacy to Anti-PD-1 PD-L1 Agents in Non Small Cell Lung Cancer Patients Recruiting
Urinary Microbiome Differences in Bladder Cancer, Benign Urinary Diseases and Healthy Counterparts in Adult Male Population Recruiting
MALE Mamm Organoids Recruiting
Chemo-Radiotherapy Boost Treatment Guided by Perfusion MRI on Hypoxic Zones in Head and Neck Cancer Active, not recruiting

Other trials for the same condition

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) Recruiting
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer Recruiting
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer Recruiting
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016) Recruiting
Establishment of a Tumor Bank for Blood Samples Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06875414 on ClinicalTrials.gov ↗ ← All trials in Italy